Danish Biotech Weekly – Week 24

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, several companies reported positive results from trials including Initiator Pharma, Curasight and Fluoguide. Fluoguide only rose by 4% while Curasight fell by 1%. Their week performance following the announcements can be explained by the companies’ already strong year-to-date performance.

7 of the 20 listed, Danish biotech companies have published news the past week. 11 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Saniona is now the best performing stock this year.

Company news the past week

Ascendis Pharma

Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany (Link)

Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Link)

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

No news the past week

Curasight

Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma) (Link)

Evaxion Biotech

No news the past week

Expres2ion

No news the past week

Fluoguide

FluoGuide announces positive topline results from phase IIa trial of FG001 in lung cancer (Link)

Genmab

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 (Link)

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (Link)

Gubra

Gubra announces updates to its pipeline. Internally developed brain-accessible orexin peptides for the treatment of narcolepsy, now ready for partnering (Link)

Initiator Pharma

Initiator Pharma reports dose-dependent significant efficacy of IP2018 in the placebo-controlled Phase IIa clinical trial of Erectile Dysfunction (Link)

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

Zealand Pharma to Participate in Upcoming Healthcare Conferences (Link)

Y-mAbs Therapeutics

No news the past week

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS

The majority of the Danish Biotech stocks delivered a negative share price performance last week. The average return was however positive with 2.4%. Initiator Pharma rose 35% after they reported positive phase IIb studies with IP2018 against erectile dysfunction. Fluoguide rose just 4% after positive phase 2 results from its lead candidate FG001, which can make cancer cells luminescent. However, the explanation may be that the stock is already up 134% year-to-date. Curasight A/S, Fluoguide A/S and Saniona AB have been the best performing stocks year-to-date after soaring 134-154% after among other things partnerships and positive recommendations paving the way for approvals.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email